Last quarter (Q4 2023), Bioline RX Ltd Sponsored ADR's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Bioline RX Ltd Sponsored ADR's net income was $―. See Bioline RX Ltd Sponsored ADR’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	$ 4.80M	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	$ 3.69M	-	-	-	-
Gross Profit	-	$ 1.11M	-	-	-	-
Operating Expense	$ 14.68M	$ 50.80M	$ 31.32M	$ 25.78M	$ 22.93M	$ 28.11M
Operating Income	$ -14.68M	$ -49.70M	$ -31.32M	$ -25.78M	$ -22.93M	$ -28.11M
Net Non Operating Interest Income Expense	$ -457.00K	$ -162.00K	$ 694.00K	$ 559.00K	$ -1.26M	$ -1.08M
Other Income Expense	$ 847.00K	$ 10.82M	$ -22.77M	$ -50.41M	$ -5.84M	$ 3.74M
Pretax Income	$ -14.29M	$ -60.62M	$ -30.62M	$ -25.22M	$ -30.02M	$ -25.45M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -14.29M	$ -60.62M	$ -24.95M	$ -27.05M	$ -30.02M	$ -25.45M
Basic EPS	$ -0.30	$ -0.06	$ -0.03	$ -0.04	$ -1.80	$ -2.55
Diluted EPS	$ -0.30	$ -0.06	$ -0.03	$ -0.04	$ -1.80	$ -2.55
Basic Average Shares	$ 97.08M	$ 963.37M	$ 773.96M	$ 662.93M	$ 16.86M	$ 9.76M
Diluted Average Shares	$ 97.08M	$ 963.37M	$ 831.70M	$ 662.93M	$ 16.86M	$ 9.76M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 14.68M	$ 54.49M	$ 31.32M	$ 25.78M	$ 22.93M	$ 28.11M
Net Income From Continuing And Discontinued Operation	$ -14.29M	$ -60.62M	$ -24.95M	$ -27.05M	$ -30.02M	$ -25.45M
Normalized Income	$ -14.29M	-	-	-	$ -24.74M	$ -29.24M
Interest Expense	$ 646.00K	-	-	-	$ 1.47M	$ 1.85M
EBIT	$ -13.64M	-	$ -32.41M	$ -26.21M	$ -28.55M	$ -23.59M
EBITDA	$ -13.35M	-	$ -33.02M	$ -26.87M	$ -27.62M	$ -22.65M

Currency in USD

Bioline RX Ltd Sponsored ADR Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing